This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PEAR Pear Therapeutics (PEAR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Pear Therapeutics Stock (NASDAQ:PEAR) 30 days 90 days 365 days Advanced Chart Get Pear Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume66.30 million shsAverage Volume7.75 million shsMarket Capitalization$4.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts. Read More Receive PEAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pear Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PEAR Stock News HeadlinesDigital Health Isn't the Future — It's the New Standard of CareJuly 1, 2025 | usatoday.comSingapore’s Temasek cuts back on start-up investmentsJune 4, 2025 | ft.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer. | Timothy Sykes (Ad)$19.75+ Bn Digital Therapeutics Markets, 2035 - Rising Demand and Stakeholder Investment Drive ExpansionMay 22, 2025 | uk.finance.yahoo.comRachel Reeves tries cell sorting experiments at Quell TherapeuticsNovember 14, 2024 | msn.com49 US startups have become unicorns so far in 2024: Here’s the full listOctober 25, 2024 | techcrunch.comTVibes for digital health deals improve after slumpOctober 22, 2024 | msn.comPursueCare Introduces RESET® and RESET-O®—FDA-Authorized Digital Therapeutics for Addiction TreatmentOctober 16, 2024 | finance.yahoo.comSee More Headlines PEAR Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Pear Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pear Therapeutics investors own include Meta Platforms (META), LyondellBasell Industries (LYB), AbCellera Biologics (ABCL), atai Life Sciences (ATAI), CVS Health (CVS), uniQure (QURE) and Absci (ABSI). Company Calendar Today7/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Health services Sub-IndustryN/A Current SymbolNASDAQ:PEAR CIK1835567 Webpeartherapeutics.com Phone617-925-7848FaxN/AEmployees300Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$75.49 million Net Margins-594.70% Pretax Margin-594.70% Return on Equity-217.85% Return on Assets-95.20% Debt Debt-to-Equity RatioN/A Current Ratio1.48 Quick Ratio1.48 Sales & Book Value Annual Sales$12.69 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / BookN/AMiscellaneous Outstanding Shares142,739,000Free Float98,918,000Market Cap$4.17 million OptionableNot Optionable Beta0.45 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:PEAR) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pear Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pear Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
